Information Provided By: 
Fly News Breaks for August 26, 2016
HOLX
Aug 26, 2016 | 11:12 EDT
Piper Jaffray analyst William Quirk noted that the FDA has revised its Zika screening guidance to recommend testing of donated blood in all states and thinks this protocol could help Hologic add between $13M-$25M in revenue. Quirk expects the impact for Hologic to be "quite small" given the current spread of the virus, but said he will be watching how the second identified mosquito vector spreads the disease. The analyst keeps a Neutral rating and $44 price target on Hologic shares, which are up about 1% to $38.78 in morning trading.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
